ArticleJournal of cystic fibrosis : official journal of the European Cystic Fibrosis Society2023

Willingness of people with cystic fibrosis receiving elexacaftor/tezacaftor/ivacaftor (ETI) to participate in randomized modulator and inhaled antimicrobial clinical trials.

D R VanDevanter et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.